Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans
about
Potential protective properties of flax lignan secoisolariciresinol diglucosideNovel synthetic (S,S) and (R,R)-secoisolariciresinol diglucosides (SDGs) protect naked plasmid and genomic DNA From gamma radiation damageEnterolactone Induces G1-phase Cell Cycle Arrest in Nonsmall Cell Lung Cancer Cells by Downregulating Cyclins and Cyclin-dependent Kinases.Flaxseed for hypertension: implications for blood pressure regulation.Antidiabetic effect of enterolactone in cultured muscle cells and in type 2 diabetic model db/db mice.Absorption of plant lignans from cereals in an experimental pig model.Induced Mutagenesis in UGT74S1 Gene Leads to Stable New Flax Lines with Altered Secoisolariciresinol Diglucoside (SDG) Profiles.Detection of novel metabolites of flaxseed lignans in vitro and in vivo.Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3.An altered tissue distribution of flaxseed lignans and their metabolites in Abcg2 knockout mice.Targeted Metabolomics Analysis Identifies Intestinal Microbiota-Derived Urinary Biomarkers of Colonization Resistance in Antibiotic-Treated Mice.Influence of Flaxseed Lignan Supplementation to Older Adults on Biochemical and Functional Outcome Measures of Inflammation.Binding of enterolactone and enterodiol to human serum albumin: increase of cysteine-34 thiol group reactivity.Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats.Cloning, expression, and characterization of a four-component O-demethylase from human intestinal bacterium Eubacterium limosum ZL-II.
P2860
Q26799230-3E0571CD-BDDA-4E6C-965A-EAE0745706E1Q30062185-47EA49FC-1BD2-43B4-9F93-8080E0DEB5D5Q33880164-00B31ED7-7A57-49E2-96D1-BA559ED43ED6Q38262477-A94AE3DB-EAF2-4CCE-A31B-C096244377B2Q38784400-4E5B5729-946D-4F63-A52E-933C1E0A8F7AQ39899989-335846EA-D6B8-467F-A9CD-1432EEEA49BAQ41875236-CAB16034-9B02-4B45-8D80-C8C17A2C7905Q46596459-4F9278BF-FA32-43CC-8A7F-F809AA98F350Q47206463-BDD5DD8C-59FB-46BB-B672-E0C3B873EFF6Q47239710-7D5AACDC-F190-4840-B09B-EDBF1D6E5F37Q47865781-10CAAC57-7353-4473-9B51-1712E2244541Q47968289-ED1C6978-849A-46F1-B343-8EE98D7FCA62Q53189381-FBFA6AE8-AF4B-4A20-9EB5-2EC50ABCA0ADQ53596757-1AEFB90C-1842-47D2-862C-4504723B818CQ53604101-8283B97E-37F4-46E0-8E01-90F05A072062
P2860
Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolism of secoisolaricires ...... lignan enterolactone in humans
@en
Metabolism of secoisolaricires ...... ignan enterolactone in humans.
@nl
type
label
Metabolism of secoisolaricires ...... lignan enterolactone in humans
@en
Metabolism of secoisolaricires ...... ignan enterolactone in humans.
@nl
prefLabel
Metabolism of secoisolaricires ...... lignan enterolactone in humans
@en
Metabolism of secoisolaricires ...... ignan enterolactone in humans.
@nl
P2093
P2860
P356
P1433
P1476
Metabolism of secoisolaricires ...... lignan enterolactone in humans
@en
P2093
Brian Wolfe
James E Heubi
Kenneth D R Setchell
Linda Zimmer-Nechemias
Nadine M Brown
P2860
P304
P356
10.1039/C3FO60402K
P577
2014-03-01T00:00:00Z